The identification of patients who are at high risk for irinotecan-related severe diarrhea and neutropenia is clinically important. We conducted the first genome-wide association study (GWAS) to search for novel susceptibility genes for irinotecan-related severe toxicities, such as diarrhea and neutropenia, in non-small-cell lung cancer (NSCLC) patients treated with irinotecan chemotherapy. The GWAS putatively identified 49 single-nucleotide polymorphisms (SNPs) associated with grade 3 diarrhea (G3D) and 32 SNPs associated with grade 4 neutropenia (G4N). In the replication series, the SNPs rs1517114 (C8orf34), rs1661167 (FLJ41856) and rs2745761 (PLCB1) were confirmed as being associated with G3D, whereas rs11128347 (PDZRN3) and rs11979430 and rs7779029 (SEMAC3) were confirmed as being associated with G4N. The final imputation analysis of our GWAS and replication study showed significant overlaps of association signals within these novel variants. This GWAS screen, along with subsequent validation and imputation analysis, identified novel SNPs associated with irinotecan-related severe toxicities.
INTRODUCTION
Irinotecan is one of the most active chemotherapeutic agents for patients with colorectal and lung cancers. However, some patients suffer from irinotecan-related severe toxicities, such as diarrhea and neutropenia. 1 Although comprehensive data supporting the association between homozygous UGT1A1*28 and grade 4 neutropenia exist, this association does not account for all toxicities observed with irinotecan chemotherapy. 2--4 Furthermore, genetic variations in other UGT1A genes and drug transporters have been suggested to contribute to the variability of irinotecan pharmacokinetics and toxicities. 5--8 Previously, we investigated the associations of variants in other UGT1A genes and transporters with irinotecan pharmacokinetics and toxicity in Korean nonsmall-cell lung cancer (NSCLC) patients treated with irinotecanbased chemotherapy. 9--11 We found that the UGT1A1*6/*6 and SLCO1B1 521TC or CC genotypes were associated with a significantly higher area under the curve (AUC) of SN-38, an active metabolite of irinotecan, and were independently predictive for grade 4 neutropenia (G4N). Although no significant pharmacokinetic parameters for severe diarrhea were found, the UGT1A9*22 9/9, ABCC2 3972CC and ABCG2 34GA or AA genotypes were independently predictive for grade 3 diarrhea (G3D). 12 Nevertheless, much of the variation in irinotecan pharmacokinetics and toxicity remains unexplained.
Owing to the severity of irinotecan-related toxicity, identification of patients who are at high risk for severe diarrhea and neutropenia is clinically essential. To date, irinotecan pharmacogenetic studies have mainly consisted of association analyses of candidate genes. However, the toxicity phenotypes of cancer patients are complicated by many factors; thus, a more comprehensive and systemic approach is needed. The recent development of new-generation and cost-effective high-throughput technologies has paved the way for a genome-wide association study (GWAS) to identify novel susceptibility genes. 13 Therefore, we conducted the first GWAS to search for novel genes involved in susceptibility to irinotecan-related severe toxicity, such as diarrhea and neutropenia, in NSCLC patients treated with irinotecan chemotherapy.
MATERIALS AND METHODS

Study population
To construct a relatively homogenous treatment group, we restricted patients who participated in clinical trials and received irinotecan-based chemotherapy as first-line therapy for their advanced NSCLC. In addition, we collected toxicity data prospectively through clinical trials. For the initial GWAS discovery stage, cases and controls were obtained from two phase II studies of irinotecan and cisplatin chemotherapy, which enrolled chemonaive patients with advanced NSCLC. A total of 81 patients received irinotecan 80 mg m À2 intravenously (i.v.) on days 1 and 8 plus cisplatin 60 mg m À2 i.v. on day 1 every 3 weeks, whereas 22 patients were treated with irinotecan 65 mg m À2 and cisplatin 30 mg m À2 i.v. on days 1 and 8 every 3 weeks. Full details of the studies have been reported previously. 14, 15 The significance of the single-nucleotide polymorphisms (SNPs) identified at the discovery stage was subsequently confirmed through a replication study in independent subjects enrolled in another randomized phase II study of irinotecan-based chemotherapy, which also recruited chemo-naive patients with advanced NSCLC. In this study, 73 patients received irinotecan 80 mg m À2 i.v. on days 1 and 8 plus cisplatin 60 mg m À2 i.v. on day 1 every 3 weeks, and 73 patients received irinotecan 90 mg m À2 i.v. on days 1 and 8 plus oral capecitabine 1000 mg m À2 twice daily on days 1 through 14 every 3 weeks. These studies were conducted under the approval of the ethical review boards and the guidelines for good clinical practice. All subjects gave informed consent for the genetic testing.
Definition of case and control for irinotecan-related severe toxicities Our goal was to find novel genetic variants associated with irinotecanrelated severe diarrhea and neutropenia through a GWAS. Cases were required to have G3D or G4N during the course of irinotecan-based chemotherapy. Controls had not experienced G3D or G4N during irinotecan-based chemotherapy. Toxicity was assessed throughout treatment and was graded using the National Cancer Institute's Common Terminology Criteria (NCI-CTC version 2.0).
Genotyping and quality control
Peripheral blood samples were obtained at baseline, and genomic DNA was extracted using a QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA) in accordance with the manufacturer's instructions. A genome-wide scan was performed using an Affymetrix Genome-Wide Human SNP array 5.0 (Affymetrix, Santa Clara, CA, USA) comprising 440 094 genome-wide SNPs. Genotype calls were determined from the fluorescence intensities using the DM algorithm with a 0.33 P-value setting, as well as the B-RLMM algorithm.
Quality control procedures included the following steps. First, only samples with at least 95% call rate were included. SNPs with a call rate o95% in each panel of case or control were discarded. Second, SNPs deviating from Hardy--Weinberg equilibrium in controls (Po0.001) were not included in the w 2 test. Finally, those with a minor allele frequency of 40.05 were included for analysis.
Based on the initial GWAS results, we selected the most promising SNPs for subsequent genotyping in the replication sample according to the following inclusion criteria: (1) Po1 Â 10 À4 in the GWAS allelic association analyses and (2) minor allele frequency in the case population (G3D or G4N) of X0.15. Genotyping was performed using an iPLEX Gold assay on the MassARRAY platform (Sequenom, San Diego, CA, USA) based on matrix-assisted laser desorption/ionization time-of-flight spectrometry, according to the manufacturer's instructions. 16 For quality control of the genotyping assay, 10% of the samples were run as duplicates and tested for concordance. Additionally, genotype clusters were examined manually to determine their fitness. The resultant genotype data were collected using Typer software (Sequenom, version 4.0).
Statistical analysis
The association of a specific SNP with G3D or G4N was analyzed by comparing the minor allele frequencies of the cases and controls, with significance determined by P-values of Jonckheere--Terpstra tests. The odds ratio of cases with a selected SNP compared with the controls and its relevant 95% confidence intervals were determined. As the sample size was small, the thresholds for declaring significance were Po1.0 Â 10 À4 for the GWAS and Po0.05 for the replication study. All association tests were based on the comparison of alleles. PLINK 1.07 and SAS 9.1.3 (SAS Institute, Cary, NC, USA) were used for statistical analysis. Linkage disequilibrium (LD) analysis was quantified with Haploview, version 4.2 (http://www. broadinstitute.org/haploview/haploview). 17 For the genomic regions of interest, the IMPUTE program version 1 (https://mathgen.stats.ox.ac.uk/ impute/impute_v1.html) was utilized to impute the genotypes of all SNPs located in the regions based on Asian HapMap data. 18 
RESULTS
GWAS discovery and identification of novel SNPs
The study design included an initial GWAS discovery stage and a follow-up replication and validation stage. The characteristics of the respective samples are detailed in Table 1 . In the GWAS discovery stage, 312 230 SNPs passed the quality control criteria for GWAS analysis for G4D and G3D. We found 137 SNPs for G3D and 42 SNPs for G4N with Po1.0 Â 10 À4 . The association P-values were very modest, with only one reaching the established genome-wide significance level at 10 À7 (best P ¼ 6.9 Â 10
À8
). The distribution of P-values across the genome is illustrated in Figure 1 . After discarding the SNPs whose minor allele frequency in the cases (G3D or G4N) was o0.15, we identified 48 SNPs for G3D and 31 SNPs for G4N. Next, we proceeded to replicate these associations in an independent NSCLC patient population receiving an irinotecan-based chemotherapy. The replication analysis revealed the three most significantly associated SNPs for each toxicity. The significant associations observed in the GWAS and the replication study are shown in Table 2 . rs1517114 in intron 3 of C8orf34 (chromosome 8 open reading frame 34), rs1661167 in the 3 0 untranslated region of FLJ41856 (CEACAM22P (carcinoembryonic antigen-related cell adhesion molecule 2, pseudogene)) and rs2745761 in intron 2 of PLCB1 (phospholipase C, b1) showed strong associations with G3D. Regarding G4N, rs11128347 in intron 3 of PDZRN3 (PDZ domain--containing ring finger 3) and two SNPs (rs11979430 and rs7779029) located close to SEMA3C (sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C) on chromosome 7 showed strong associations. A statistically significant LD was observed between rs11979430 and rs7779029 (r 2 ¼ 0.911). Upon combining the GWAS and replication results, the statistical significances were significantly improved for all of these SNPs. The combined P-values for these SNPs are summarized in Table 2 .
Validation and missing data imputation at the genotyped SNPs To provide independent estimates of genotypes associated with G3D or G4N, we imputed all of the known SNPs in the 50-kb region of interest based on the genotyped SNPs. The imputed association signals in the combined samples (GWAS þ replication) are plotted in Supplementary Figures 1--4 . According to the imputation results in the combined GWAS and replication data set, 47 SNP markers for G3D and 26 SNP markers for G4N achieved P-values of o1 Â 10 À4 . Among them, 22 SNPs showed a stronger association with G3D, which achieved a combined P-value of o1 Â 10 À5 and were located within a 24.5-kb LD block of C8orf23 intron 3 and an 11.9-kb LD block of PLCB1 intron 2. Regarding G4N, 16 SNPs achieved a combined P-value of o1 Â 10
À5
; these were located within a 42.6-kb LD block of PDZRN3 intron 3. Detailed information for the plotted SNPs is presented in Table 3 .
Previously described genetic associations Previously, we found that UGT1A1*6 and SLCO1B1 521T4C were significantly associated with irinotecan-related G4N. Moreover, UGT1A9*22, ABCC2 3972C4T and ABCG2 34G4A were associated with irinotecan-related G3D. Thus, we investigated their effects on irinotecan-related G4N or G3D in the present study. Table 4 shows the analysis of SNPs in the previously mentioned genes. Whereas UGT1A1 was present in our GWAS panel, the remaining four SNPs were not present. Thus, we analyzed these four SNPs in the replication samples (Table 4) . Although UGT1A1*6 failed to reach genome-wide significance, the combined analysis showed that homozygous UGT1A1*6 was significantly associated with G4 neutropenia. Additionally, the ABCC2 3972 C4T and SLCO1B1 521T4C variants were significantly associated with G3D and G4N, respectively, in the replication stage.
DISCUSSION
This study represents the first GWAS for severe diarrhea and neutropenia, which are clinically important and potentially fatal toxicities for cancer patients treated with irinotecan chemotherapy. Through the GWAS, we identified new SNPs potentially associated with irinotecan-related severe diarrhea and neutropenia in Korean patients with NSCLC. The follow-up stage confirmed the associations of SNPs with irinotecanrelated severe diarrhea and neutropenia, as the associations were replicated in an independent NSCLC patient sample. Furthermore, imputation analysis of our GWAS and replication study showed significant overlaps of the association signals.
We demonstrated that 47 and 26 SNPs showed strong associations (Po1 Â 10
À4
) with G3D and G4N, respectively. In particular, a narrow 11.9-kb window of intron 2 of PLCB1 contained 7 SNPs that achieved P-values of o1 Â 10 À5 and showed complete LD with rs274561. Additionally, 13 SNPs in intron 3 of C8orf34 achieved P-values of o1 Â 10 À5 and showed high LD with rs1517114. According to our imputation analysis for G4N, 16 SNPs in intron 3 of PDZRN3 achieved P-values of o1 Â 10 À5 and showed complete LD with rs11128347. Nine additional SNPs in intron 2 of SEMA3C achieved P-values of o1 Â 10 À4 . Among the candidate genes identified in our study for G3D, PLCB1 has been implicated in gastrointestinal mucositis after irinotecan therapy in an animal study.
A microarray investigation found more than 500 genes, including PLCB1, to be significantly altered by irinotecan in the rat gut. 19 PLCB1 has also been implicated in severe ulcerative colitis. 20 The protein encoded by PLCB1 catalyzes the formation of inositol 1,4,5-trisphosphate and diacylglycerol from phosphatidylinositol 4,5-bisphosphate. This reaction uses calcium as a cofactor and plays an important role in the intracellular transduction of many extracellular signals. PLCB1 is activated by two G-protein a subunits, a-q and a-11. Two transcript variants encoding different isoforms have been found for PLCB1 (provided by RefSeq. http:// www.ncbi.nlm.nih.gov/gene/23236).
C8orf34 encodes a protein that is related to cyclic AMP (cAMP)--dependent protein kinase regulators. The cAMP-dependent protein kinase pathway mediates the intestinal secretary process, which leads to severe diarrhea. 21 This relationship suggests that genetic variants of C8orf34 may be associated with treatmentrelated severe diarrhea.
There is accumulating evidence that plasma exposure to SN-38 is associated with an increased risk of irinotecan-related severe toxicity, primarily neutropenia. The genetic variants of UGT1A1, which is responsible for bilirubin glucuronidation, have been associated with reduced glucuronidation of SN-38 and increased severe neutropenia in patients treated with irinotecan.
2--4 Previously, we found that the absolute neutrophil count was negatively correlated with the SN-38 AUC and that patients who experienced G4N had a significantly higher SN-38 AUC. 9, 12 Moreover, a higher baseline total bilirubin level was correlated with a significantly lower absolute neutrophil count nadir during irinotecan chemotherapy. 12 Thus, lower bilirubin glucuronidation activity contributes to a higher SN-38 AUC, which results in severe neutropenia.
The PDZRN3 gene is expressed in a variety of organs and tissues, including the heart, skeletal muscle and liver. In skeletal muscle, the expression of PDZRN3 is developmentally regulated. This protein is essential for differentiation of myoblasts into myotubes. 22 Depletion of PDZRN3 by RNA interference revealed that PDZRN3 inhibits the upregulation of alkaline phosphatase activity in vitro. 23 Furthermore, PDZRN3 is frequently downregulated or deleted in various cancers, including biliary tract cancer. 24 These findings suggest that the genetic variants of PDZRN3 may affect bilirubin glucuronidation, which may lead to a decrease in SN-38 glucuronidation and ultimately the development of severe neutropenia.
SEMA3C is a secreted protein that may be involved in cell survival mechanisms. It is expressed intensely in the heart, skeletal muscle, colon, small intestine, ovary, testis and prostate. It shows faint expression ubiquitously among other organs, including the brain. It binds with high affinity to the receptor NRP2 (http:// www.phosphosite.org/proteinAction.do?id ¼ 2380717&showAllSi-tes ¼ true). A genome-wide association meta-analysis revealed that variants in SEMA3C are associated with total serum bilirubin level, as are UGT1A1 and SLCO1B1. 25 Because the plasma concentration of SN-38 is strongly correlated with total serum bilirubin level, SEMA3C variants may lead to severe neutropenia after irinotecan treatment.
Recently, other group reported several candidate SNPs that might help to predict the outcome of platinum-based chemotherapy in NSCLC. 26 However, the efficacy of chemotherapy or patients' survival can be affected by many factors such as the drug combination and the subsequent salvage chemotherapies given to patients. Thus, we analyzed the effects of GWAS on toxicity only in this study. Despite the small number of patients, we collected the toxicity data prospectively throughout the clinical trials using the same toxicity criteria. However, this study has some considerable limitations. First, patients received different doses of irinotecan. However, previously we had demonstrated that the incidences of G3 and G4 were not significantly different according to the irinotecan dose schedules. 10 Second, different drugs were used in combination with irinotecan. As cisplatincontaining regimens are more likely to develop neutropenia compared with non-platinum regimens, patients in the GWAS stage showed a trend toward higher incidence of G4N than those in the replication stage (24% vs 14%, P ¼ 0.06). This finding suggests that cisplatin combination in the GWAS stage may affect discovering SNPs for G4N. However, fewer patients received cisplatin in the replication stage. Furthermore, there was no difference in G3D between two groups (11% vs 9%, P ¼ 0.604). These findings suggest that the replication samples are more likely to represent irinotecan-related toxicities rather than cisplatin. Thus, validation though the replication stage may contribute to select SNPs associated with irinotecan-related G4N. Third, the power to detect genome-wide significance was low because of the small sample size. Finally, the biologic mechanisms underlying these associations are still unknown.
In summary, this GWAS in Korean patients with NSCLC identified potential candidate gene regions that are associated with irinotecan-related severe diarrhea and neutropenia. This is the first study to explore the genetic variants in irinotecan-related severe toxicities on a genome-wide scale. Follow-up functional validation and replication studies in the larger cohort are needed to confirm our findings.
